Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence

Cardiovascular Diseases Clinical Trial

Official title: Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence: A Parallel Single-blinded Randomized Trial

Status Completed

Clinical Trial Summary

This is a pilot study that was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers. we advocate comparing the clinical efficacy rather than simple bioequivalence comparison.

Clinical Trial Description

Cardiovascular diseases are the leading cause of death worldwide. Ticagrelor, is an oral antiplatelet drug used in acute coronary syndrome. Although generic drugs are approved for their bioequivalence to the original product, they are not necessarily to be therapeutically equivalent. This study was conducted to prove the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers. A loading dose of 180 mg ticagrelor named Brilique® or Ticaloguard® followed by a 90 mg twice daily regimen as maintenance dose was given to 14 and 15 volunteers in Ticaloguard and Brilique groups, respectively. The platelet aggregation on adenosine diphosphate (ADP) agonist was assessed at different time intervals . ;

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Cardiovascular Diseases

• NCT number: NCT05474053
• Study type: Interventional
• Source: Cairo University
• Status: Completed
• Phase: Phase 3
• Start date: November 13, 2021
• Completion date: November 28, 2021